Abstract

Prostate cancer is the fifth leading cause of cancer-related death among men with the majority of deaths linked to metastatic disease. Accumulating clinical data have confirmed the substantial survival benefit of the addition of docetaxel or androgen signaling inhibitors to androgen deprivation therapy for the treatment of metastatic castration-sensitive prostate cancer (mCSPC). Apalutamide, a next-generation androgen receptor inhibitor, has recently been shown to provide an added survival benefit in the treatment of mCSPC and consequently approved for this indication. This review summarizes the body of evidence with regards to the preclinical activity and clinical efficacy of apalutamide with a specific focus on its efficacy in the treatment of mCSPC.

Keywords:

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68(6), 394–424 (2018).
MedlineGoogle Scholar
2. Hu JC, Nguyen P, Mao J et al. Increase in prostate cancer distant metastases at diagnosis in the United States. JAMA Oncol. 3(5), 705–707 (2017).
MedlineGoogle Scholar
3. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. J. Am. Med. Assoc. 281(17), 1591–1597 (1999).
Medline CASGoogle Scholar
4. Neal DE, Metcalfe C, Donovan JL et al. Ten-year mortality, disease progression, and treatment-related side effects in men with localised prostate cancer from the ProtecT randomised controlled trial according to treatment received. Eur. Urol. 77(3), 320–330 (2020).
MedlineGoogle Scholar
5. Culp MBB, Soerjomataram I, Efstathiou JA, Bray F, Jemal A. Recent global patterns in prostate cancer incidence and mortality rates. Eur. Urol. 77(1), 38–52 (2020).
MedlineGoogle Scholar
6. Buelens S, De Bleser E, Dhondt B et al. Importance of metastatic volume in prognostic models to predict survival in newly diagnosed metastatic prostate cancer. World J. Urol. 37(12), 2565–2571 (2019).
Medline CASGoogle Scholar
7. Sweeney CJ, Chen Y-H, Carducci M et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N. Engl. J. Med. 373(8), 737–746 (2015).
Medline CASGoogle Scholar
8. Francini E, Gray KP, Xie W et al. Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC). Prostate 78(12), 889–895 (2018).
Medline CASGoogle Scholar
9. Halabi S, Kelly WK, Zhou H et al. The site of visceral metastases (mets) to predict overall survival (OS) in castration-resistant prostate cancer (CRPC) patients (pts): A meta-analysis of five Phase III trials. J. Clin. Oncol. 32(Suppl. 15), 5002–5002 (2014).
Google Scholar
10. Fizazi K, Massard C, Smith MR et al. Baseline covariates impacting overall survival (OS) in a Phase III study of men with bone metastases from castration-resistant prostate cancer. J. Clin. Oncol. 30(Suppl. 15), 4642–4642 (2012).
Google Scholar
11. National Cancer Institute. Browse the SEER Cancer Statistics Review 1975–2016. https://seer.cancer.gov/csr/1975_2016/browse_csr.php?sectionSEL=23&pageSEL=sect_23_zfig.06
Google Scholar
12. Huggins C, Stevens RE, Hodges CV. Studies on prostatic cancer: II. The effects of castration on advanced carcinoma of the prostate gland. Arch. Surg. 43(2), 209–223 (1941). • This study established the utility of androgen ablation for the treatment of prostate cancer.
CASGoogle Scholar
13. Tolis G, Ackman D, Stellos A et al. Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. Proc. Natl Acad. Sci. U. S. A. 79(5), 1658–62 (1982).
Medline CASGoogle Scholar
14. Taylor CD, Elson P, Trump DL. Importance of continued testicular suppression in hormone-refractory prostate cancer. J. Clin. Oncol. 11(11), 2167–72 (1993).
Medline CASGoogle Scholar
15. James ND, Spears MR, Clarke NW et al. Survival with newly diagnosed metastatic prostate cancer in the docetaxel era: Data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019). Eur. Urol. 67(6), 1028–1038 (2015).
MedlineGoogle Scholar
16. National Comprehensive Cancer Network. Prostate. https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf
Google Scholar
17. Chi KN, Agarwal N, Bjartell A et al. Apalutamide for metastatic, castration-sensitive prostate cancer. N. Engl. J. Med. 381(1), 13–24 (2019). •• The TITAN trial established the efficacy and safety of apalutamide for the treatment of metastatic castration-sensitive prostate cancer.
Medline CASGoogle Scholar
18. Davis ID, Martin AJ, Stockler MR et al. Enzalutamide with standard first-line therapy in metastatic prostate cancer. N. Engl. J. Med. 381(2), 121–131 (2019).
Medline CASGoogle Scholar
19. Armstrong AJ, Szmulewitz RZ, Petrylak DP et al. Arches: a randomized, Phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J. Clin. Oncol. 37(32), 2974–2986 (2019).
Medline CASGoogle Scholar
20. Fizazi K, Tran N, Fein L et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N. Engl. J. Med. 377(4), 352–360 (2017).
Medline CASGoogle Scholar
21. Fizazi K, Tran NP, Fein L et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, Phase 3 trial. Lancet Oncol. 20(5), 686–700 (2019).
Medline CASGoogle Scholar
22. James ND, de Bono JS, Spears MR et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N. Engl. J. Med. 377(4), 338–351 (2017).
Medline CASGoogle Scholar
23. James ND, Sydes MR, Clarke NW et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet 387(10024), 1163–1177 (2016).
Medline CASGoogle Scholar
24. Clarke NW, Ali A, Ingleby FC et al. Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 30(12), 1992–2003 (2019).
Medline CASGoogle Scholar
25. Kyriakopoulos CE, Chen YH, Carducci MA et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 chaarted trial. J. Clin. Oncol. 36(11), 1080–1087 (2018).
Medline CASGoogle Scholar
26. von Deutsch DA, Abukhalaf IK, Lapu-Bula R. Anabolic doping agents. In: Handbook of Drug Interactions. Humana Press, NJ, USA, 625–754 (2012).
Google Scholar
27. Chen Y, Clegg NJ, Scher HI. Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. Lancet Oncol. 10( 10), 981–991 (2009).
MedlineGoogle Scholar
28. Nishiyama T, Hashimoto Y, Takahashi K. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer. Clin. Cancer Res. 10(21), 7121–7126 (2004).
Medline CASGoogle Scholar
29. Mohler JL, Gregory CW, Ford H et al. The androgen axis in recurrent prostate cancer. Clin. Cancer Res. 10(2), 440–448 (2004).
Medline CASGoogle Scholar
30. Montgomery RB, Mostaghel EA, Vessella R et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 68(11), 4447–4454 (2008).
Medline CASGoogle Scholar
31. Stanbrough M, Bubley GJ, Ross K et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 66(5), 2815–2825 (2006).
Medline CASGoogle Scholar
32. Harris WP, Mostaghel EA, Nelson PS, Montgomery B. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat. Clin. Pract. Urol. 6(2), 76–85 (2009).
Medline CASGoogle Scholar
33. Keller ET, Ershler WB, Chang C. The androgen receptor: a mediator of diverse responses. Front. Biosci. 1, d59–d71 (1996).
Medline CASGoogle Scholar
34. Chang C, Kokontis J, Liao S. Molecular cloning of human and rat complementary DNA encoding androgen receptors. Science 240(4850), 324–326 (1988).
Medline CASGoogle Scholar
35. Lubahn DB, Joseph DR, Sullivan PM, Willard HF, French FS, Wilson EM. Cloning of human androgen receptor complementary DNA and localization to the X chromosome. Science 240(4850), 327–330 (1988).
Medline CASGoogle Scholar
36. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr. Rev. 25(2), 276–308 (2004).
Medline CASGoogle Scholar
37. Heinlein CA, Chang C. Androgen receptor (AR) coregulators: an overview. Endocr. Rev. 23(2), 175–200 (2002).
Medline CASGoogle Scholar
38. Lu S, Tsai SY, Tsai MJ. Regulation of androgen-dependent prostatic cancer cell growth: androgen regulation of CDK2, CDK4, and CKI p16 genes. Cancer Res. 57(20), 4511–4516 (1997).
Medline CASGoogle Scholar
39. Lu S, Liu M, Epner DE, Tsai SY, Tsai MJ. Androgen regulation of the cyclin-dependent kinase inhibitor p21 gene through an androgen response element in the proximal promoter. Mol. Endocrinol. 13(3), 376–384 (1999).
Medline CASGoogle Scholar
40. Kimura K, Markowski M, Bowen C, Gelmann EP. Androgen blocks apoptosis of hormone-dependent prostate cancer cells. Cancer Res. 61(14), 5611–5618 (2001).
Medline CASGoogle Scholar
41. Dai C, Heemers H, Sharifi N. Androgen signaling in prostate cancer. Cold Spring Harb. Perspect. Med. 7(9), (2017).
MedlineGoogle Scholar
42. Ferraldeschi R, Welti J, Luo J, Attard G, De Bono JS. Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects. Oncogene 34( 14), 1745–1757 (2015).
Medline CASGoogle Scholar
43. Rathkopf DE, Morris MJ, Fox JJ et al. Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer. J. Clin. Oncol. 31(28), 3525–3230 (2013). • The study gives details regarding the safety profile and pharmakokinetic/pharmakodynamic activity of apalutamide in human patients.
Medline CASGoogle Scholar
44. Clegg NJ, Wongvipat J, Joseph JD et al. ARN-509: A novel antiandrogen for prostate cancer treatment. Cancer Res. 72(6), 1494–1503 (2012). • This study details the activity of apalutamide in pre-clinical in-vitro and in-vivo models.
Medline CASGoogle Scholar
45. Rathkopf DE, Antonarakis ES, Shore ND et al. Safety and antitumor activity of apalutamide (ARN-509) in metastatic castration-resistant prostate cancer with and without prior abiraterone acetate and prednisone. Clin. Cancer Res. 23(14), 3544–3551 (2017). • This is a Phase II trial examining the activity of apalutamide for the treatment of metastatic castrate-resistant prostate cancer.
Medline CASGoogle Scholar
46. An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC). Clinical trial no. NCT02257736. https://clinicaltrials.gov/ct2/show/NCT02257736
Google Scholar
47. Smith MR, Saad F, Chowdhury S et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N. Engl. J. Med. 378(15), 1408–1418 (2018). • This study details the efficacy and safety profile of apalutamide for the treatment of nonmetastatic castrate-resistant prostate cancer.
Medline CASGoogle Scholar
48. Small EJ, Saad F, Chowdhury S et al. Final survival results from SPARTAN, a Phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC). J. Clin. Oncol. 38(Suppl. 15), 5516–5516 (2020). • This abstract details the final survival outcome of apalutamide for the treatment of nonmetastatic castrate-resistant prostate cancer.
Google Scholar
49. Saad F, Cella D, Basch E et al. Effect of apalutamide on health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the SPARTAN randomised, placebo-controlled, Phase 3 trial. Lancet Oncol. 19(10), 1404–1416 (2018).
Medline CASGoogle Scholar
50. Prostate Cancer Trialists' Collaborative Group. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Lancet 355(9214), 1491–1498 (2000).
MedlineGoogle Scholar
51. Shore ND, Chowdhury S, Villers A et al. Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): A randomised, double-blind, Phase 2 study. Lancet Oncol. 17(2), 153–163 (2016).
Medline CASGoogle Scholar
52. Penson DF, Armstrong AJ, Concepcion R et al. Enzalutamide versus bicalutamide in castration-resistant prostate cancer: the STRIVE trial. J. Clin. Oncol. 34(18), 2098–2106 (2016).
Medline CASGoogle Scholar
53. Agarwal N, McQuarrie K, Bjartell A et al. Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, Phase 3 study. Lancet. Oncol. 20(11), 1518–1530 (2019). •• In this study patient reported outcomes and health-related quality of life among patients in the TITAN trial are reported.
Medline CASGoogle Scholar
54. An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS. Clinical trial no. NCT02531516. https://clinicaltrials.gov/ct2/show/NCT02531516
Google Scholar
55. Apalutamide With Radiotherapy and Androgen Deprivation Therapy in Prostate Cancer. Clinical trial no. NCT03488810. https://clinicaltrials.gov/ct2/show/NCT03488810
Google Scholar
56. A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy. Clinical trial no. NCT03767244. https://clinicaltrials.gov/ct2/show/NCT03767244
Google Scholar
57. Testing the Addition of the Drugs, Apalutamide and Abiraterone Acetate With Prednisone, to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer. Clinical trial no. NCT04134260. https://clinicaltrials.gov/ct2/show/NCT04134260?term=apalutamide&cond=Prostate+Cancer&phase=2&draw=2&rank=9
Google Scholar
58. Conventional ADT w/or w/Out Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT. Clinical trial no. NCT03777982. https://clinicaltrials.gov/ct2/show/NCT03777982
Google Scholar
59. A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer. Clinical trial no. NCT03009981. https://clinicaltrials.gov/ct2/show/NCT03009981
Google Scholar
60. Zelefsky MJ, Gomez DR, Polkinghorn WR, Pei X, Kollmeier M. Biochemical response to androgen deprivation therapy before external beam radiation therapy predicts long-term prostate cancer survival outcomes. Int. J. Radiat. Oncol. Biol. Phys. 86(3), 529–533 (2013).
Medline CASGoogle Scholar
61. Naik M, Reddy CA, Stephans KL et al. Posttreatment prostate-specific antigen 6 months after radiation with androgen deprivation therapy predicts for distant metastasis–free survival and prostate cancer–specific mortality. Int. J. Radiat. Oncol. Biol. Phys. 96(3), 617–623 (2016).
MedlineGoogle Scholar

Vol. 16, No. 35

Metrics

Downloaded 158 times

History

Received 29 May 2020

Accepted 5 August 2020

Published online 4 September 2020

Published in print December 2020

Information

Keywords

Financial & competing interest disclosure

KN Chi has received honoraria and also research grants and funding to their institution from the following: Novartis, Janssen, Astellas, Sanofi, AstraZeneca, Roche, Pfizer. KN Chi has also received honoraria from Daiichi Sankyo and Point Biopharma. C Maurice Dror has received personal fees from Bristol-Myers Squibb, Merck Sharp and Dohme, Novartis and Medison. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Company review disclosure

In addition to the peer-review process, with the author's consent, the manufacturer of the product discussed in this article was given the opportunity to review the manuscript for factual accuracy. Changes were made by the author at their discretion and based on scientific or editorial merit only. The author maintained full control over the manuscript, including content, wording and conclusions.

PDF download

Apalutamide for the treatment of metastatic castration-sensitive prostate cancer

Abstract

References